Search Results
Search results for "Randy Hall"
Results found for "Randy Hall"
- What If the Most Important Part of Your Drug Isnât What It BindsâBut What It Does?
The answer lies in a misunderstood property called efficacyâthe power of a drug to trigger a response
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
Misreading Antagonism Delays GPCR Drug Discovery If a dose-response curve shifts to the right, you might call Fast offset kinetics allow agonists to outcompete and restore full activityâhallmarks of competitive
- Purpose-Driven Opioid Research: Catherine Demeryâs Academic Path
For others, itâs a calling. The work no longer felt like an assignmentâit felt like a calling. Catherineâs story shows that when purpose drives research, science becomes more than a jobâit becomes a calling
- How Advanced GPCR Kinetics Sharpen Decision Making (and Save You Time)
Terry Kenakin to elevate your science and sharpen your calls. signals today will shape tomorrowâs breakthroughsâand avoid delays others wonât see coming. đ Donât Fall
- Mechanism vs. Assumption: A Model-First Path to Getting GPCR MoA Right
This week, we focus on how to convert ambiguous data into confident, defensible Mechanism of Action callsâbefore This applied article walks through ligand-directed labeling, SNAP/Halo tags, and fluorescent ligands signals today will shape tomorrowâs breakthroughsâand avoid delays others wonât see coming. đ Donât Fall
- The Hidden Driver of GPCR Drug Success: Why Target Residence Time Matters More Than You Think
understand how two mechanisms intersectâand why pharmacologists are critical in addressing this crisis ⤠Call signals today will lead tomorrowâs breakthroughsâand avoid delays others wonât see coming. đ Donât Fall
- đ° GPCR Buzz: August 5-11, 2024 | Top Highlights from DrGPCR University!
GPCR University offers two live courses this fall that you wonât want to miss. News Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half
- Accelerating GPCR Drug Discovery
I call this the Lego Bucket Problem . You have the data, but not the definitive direction. đ Learn more about my services: Yamina.org đ Book a 30-minute strategy call: https://calendly.com
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
Expand your computational toolkit ⤠Call for Papers: GPCRs: Signal Transduction, Volume II Building on Donât Fall BehindâAccess the Edge You Need đ Access all the news and upcoming events ⤠đ Already a
- Why Sokhom Pin Never Left GPCRs, Even When Everyone Else Did
Scientific fads rise and fall.
- GPCRs at Discovery on Target 2026
If you work in drug discovery or biotech, Boston in the fall is where the conversation happens. We have GPCR-focused courses coming this fall as well, so stay tuned.
- đ° GPCR Weekly News, October 30 to November 4, 2023
Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 Trial Andrew Hopkins Inducted into RSC BMCS Hall
- The One Reason Why Biotech Startups Fail More Often Than They Should
đ Biotech startups rarely fail all at once. When complexity grows faster than strategy, biotech companies begin to fall apart quietly. đ This article Clarity before chaos is what prevents biotech startups from slowly falling apart. order before chaos becomes expensive What separates resilient biotech startups from those that slowly fall And in a field defined by uncertainty, that shift makes all the difference.
- Radioligands vs. Fluorescent Ligands: Binding Assays
The problem is their long half-life, which results in lower detection efficiency. Another common radioactive atom, 125I, with a higher specific activity, but a shorter half-life (60 days addition of Celt-327 to the medium. -Â Â Â Â Â Â Â Â Â Â Â Fluorescent probe design for specific targets: Â Not all Soave M, Briddon SJ, Hill SJ, Stoddart LA. Stoddart LA, Kilpatrick LE, Briddon SJ, Hill SJ.
- The Hidden Burn: How Internal Misalignment Drains Your Biotechâs Runway
Thatâs what we call the hidden burn . đ This post breaks down how biotech misalignment happens, what âs wrong, but no oneâs aligned. 2ď¸âŁ Founder-team decision asymmetry đ The founders make strategic calls It does not go away with more meetings, louder all-hands sessions, or rewritten pitch decks. đ It only decisions are made and what truly matters inside your company. 1ď¸âŁ The first shift is reframing what you call
- The Perils and Guardrails of Modifying Signalling Proteins in Bioassays
Wright and colleagues [36] demonstrated that an N-terminal 3x hemagglutinin tag narrowed activation from all hemagglutinin (HA) tag as used in structural studies narrowed the activation of Gιi/o protein subtypes from all Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor. Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior
- đ° GPCR Weekly News, February 20 to 26, 2023
All-Atom Molecular Dynamics Simulations Indicated the Involvement of a Conserved Polar Signaling Channel Slow-rising and fast-falling dopaminergic dynamics jointly adjust negative prediction error in the ventral understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia Call
- From One to Many: How a GPCR Curiosity Became a Field-Wide Toolkit
In fact, it all began with a phone call (from Bruce Merrifield, no less) encouraging Sakmar to work on pilot data came together, rotation student Ilana Kotliar  joined and pushed the project to scale across all
- When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue
The call from David â the glowing islet â created a pivot the team couldnât ignore. Two-photon microscopy revealed a glowing islet in a living mouse â a moment JB calls the âHoly Grailâ
- Chemical Drug Matter : Rethinking the Molecules We Choose to Develop In Drug Discovery
Core message: The receptor is only half the story. The molecule is the other half.
- Biotech Startup Failure: Why Teams Drift Off Course Without a Single Wrong Decision
Most biotech founders assume that failure comes from making the wrong call. A flawed experiment. Where Execution and Strategy Quietly Fall Out of Sync As drift accumulates, the first visible cracks
- Curve Shifts Donât Lie, But Your Eyes Might
When Curves Shift Some of the most difficult calls in pharmacology happen when two curves look  slightly Straight Lines, Slopes, and Systems Not all data bends into curves. Statistical Methods in Drug Discovery: Your Edge If youâre still making calls by sight, habit, or tradition
- From Venice to Virtual Molecules: Alessandro Nicoliâs Unexpected Journey into Computational Chemistry
Falling for Computational Chemistry Alessandroâs masterâs thesis brought him face to face with his âsecond Letâs embrace the challenge to study all of them.â Â
- The Quiet Power of RGS Proteins: Rethinking Pain Pathways through GPCR Biology
development, the field has remained too focused on ion channels like NAV1.8 , despite these targets falling
- Why Kinetics Matter More Than Kd in GPCR Drug Discovery
decision you make shapes your entire pipeline trajectoryâand understanding when equilibrium affinity falls All curated for speed, relevance, and immediate applicationâonly for Premium Members. lectures, classified industry news, priority event alerts, job opportunities, and insider commentaryâall Donât Fall BehindâAccess the Edge You Need đ Ready to sharpen your discovery decisions? Access this weekâs full Premium Edition here â¤Â  Access all the news and upcoming events Hashtags: #
- Nanobodies: New Dimensions in GPCR Signaling Research
All the above lightly represent the potential applications of Nbs to facilitate the development of more Tailorable half-life: Nanobodies can extend their half-life through PEGylation or fusion to serum albumin This allows for tailoring the half-life of nanobodies to increase their therapeutic window depending
- Drug Discovery Pharmacology Principles That Turn Assays Into Real Medicines
biology Disease physiology involves many interconnected systems Drug concentrations constantly rise and fall Time Matters More Than Potency For decades, discovery teams prioritized potency above all else. When PK Ends Programs Discovery teams often fall in love with molecules that show beautiful activity
- đ° GPCR Weekly News, August 7 to 13, 2023
disease therapy Primary cilia in skeletal development and disease Industry News Addex Reports 2023 Half Trial with Cancer Immunotherapy Drug HTL0039732 Exscientia Business Update for Second Quarter and First Half
- Discover the Hottest GPCR News of the Week: Oct 7-13, 2024!
Join us now, and let's explore with all our might! We aim to make education accessible to all! đ We are bouncing off the walls with excitement to meet you all and geek out about GPCRs. Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Neurocrine Biosciences Announces Conference Call Webcast of Third Quarter 2024 Financial Results Novel full MC4 receptor-specific nanobody described Call
- Terryâs Corner, Celtarys' Leap, and the $7B GPCR Horizon
Hello GPCR Minds,  This week, you'll learn all about Terryâs Pharmacology Corner, your new learning GPCR mutations in cancer  show both driver-like patterns and high redundancy, prompting a call for multiomics


























